Clinical Trials Logo

Clinical Trial Summary

Systemic lupus erythematosus (SLE) is a rare (prevalence: 40- 50/100 000 persons) heterogeneous auto-immune and auto-inflammatory disease (AD), affecting both sexes and all races, with a peak incidence / prevalence among black people and a predilection for women in the 3rd-4th decade of life. SLE is characterized by successive periods of flares and remission, which may all vary in duration and quality. Prognosis of severe forms of SLE, which affect lung, heart or brain in addition to renal involvement, has improved, but still evolution remains pejorative in a subset of patients whose 10 years mortality remains 10-15%, even in tertiary referral centers. For 20 years, no new prospective clinical trial in the course of SLE has demonstrated its effectiveness. New biological therapies have not yet made the long awaited breakthrough in the treatment of severe SLE and only anti-Blys monoclonal antibody has gained indication in moderately active SLE. In addition, serious adverse side effects (progressive multifocal leukoencephalopathy) observed with several biologics in AD patients has dampened their expected benefits. For SLE subjects resistant to 1er or 2nd line conventional treatment, there is a need to develop more effective therapies with fewer long term side effects, based on new immunomodulatory and immunosuppressive strategies. According to their in vitro immunomodulatory properties and ability to induce tissue repair mechanisms, mesenchymal stem cells (MSC) have been proposed as a new therapy for several AD, including SLE. The use of allogeneic umbilical cord-derived MSC is based on experimental and human clinical data, particularly produced by Nanjing team (Pr Sun) in China. It is also logical to select SLE patients with the same severity criteria as those used worldwide to validate the efficacy of anti-Blys therapies. Similarly, the analysis of the expected results should take into account criteria similar or comparable to those used for the pivotal clinical trials. This trial is a unique opportunity to set up collaboration between Saint-Louis APHP, clinical expert center for cell therapy in AD, and University College London for cell manufacturing.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03562065
Study type Interventional
Source Assistance Publique - Hôpitaux de Paris
Contact Dominique Farge, MD PhD
Phone 142499768
Email dominique.farge-bancel@sls.aphp.fr
Status Recruiting
Phase Phase 1/Phase 2
Start date September 11, 2019
Completion date June 1, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT03543839 - Trial of Belimumab in Early Lupus Phase 4
Terminated NCT02080195 - Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE) Phase 1/Phase 2
Completed NCT03098823 - A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE Phase 4
Recruiting NCT05545839 - Transition to Adulthood Through Coaching and Empowerment in Rheumatology N/A
Completed NCT05098600 - The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic
Completed NCT04128579 - Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis Phase 1
Recruiting NCT06161363 - Description of Compliance With Hydroxychloroquine Treatment in Patients With Systemic Lupus Erythematosus
Completed NCT03421184 - Dietary Phytoestrogens as Risk Factors for Systemic Lupus Erythematosus N/A
Not yet recruiting NCT02891213 - Study of the Role of Soluble Forms of RAGE (sRAGE/esRAGE) as Diagnostic and Prognostic Biomarkers of Systemic Lupus Erythematosus. N/A
Completed NCT01686555 - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE) Phase 1
Active, not recruiting NCT04018222 - Translation of a Diagnostic Test for Lupus Flare Prediction From Bench to Clinic
Completed NCT02747277 - Analysis of B Cells From Autoimmune Individuals
Not yet recruiting NCT06426316 - The Role of Cytokines and Regulatory T Lymphocytes in Migraine Pathophysiology. N/A
Recruiting NCT04213690 - A Pilot Study to Explore the Role of Gut Flora in Lupus
Recruiting NCT03913754 - Psycho-social Consequences of Systemic Lupus Erythematosus
Recruiting NCT06072287 - The Living With a Long-Term Condition Study
Completed NCT02455089 - Prognosis Assessment of the Increase of GADD34 Gene Expression for Patient Suffering From Systemic Lupus Erythematosus N/A
Completed NCT04089930 - Long-term Immunogenicity of a Live Herpes Zoster Vaccine in Systemic Lupus Erythematosus (SLE) Patients
Completed NCT05945784 - Exploring Accessible Beauty for Individuals With Upper Extremity Deficits
Completed NCT03253666 - Nurses' Health Study and Health Professionals Follow-Up Study (Dermatological Component)